Core Points - The World Health Organization (WHO) has updated its Essential Medicines List (EML) and the Essential Medicines List for Children (EMLc) to better align with international clinical guidelines for managing hemophilia and von Willebrand Disease (VWD) [1][2][3] - These revisions are expected to positively impact the lives of people with bleeding disorders (PWBDs) globally [1][4] Changes to EML and EMLc - New medicines added to the EML and EMLc include bi-specific monoclonal antibody emicizumab, recombinant FVIII and FIX clotting factor concentrates (CFCs), and desmopressin [7] - Plasma-derived FVIII and FIX CFCs were moved from the complementary to the core list, while both pathogen-reduced and non-pathogen reduced cryoprecipitate were removed as treatment options for hemophilia and VWD [7] - Factor IX Complex (prothrombin complex concentrate) was deleted as a therapeutic alternative to FIX CFCs [7] Impact and Collaboration - The updates to the WHO EML are seen as a significant advancement in ensuring access to modern and effective treatments for bleeding disorders [8][9] - The World Federation of Hemophilia (WFH) led a global effort involving various organizations and experts to advocate for these updates, highlighting the importance of collaboration in achieving this milestone [10][12]